메뉴 건너뛰기




Volumn 4, Issue 1, 2005, Pages 7-18

Drug interactions with angiotensin receptor blockers

Author keywords

Angiotensin II (ATII) receptor antagonists; Angiotensin receptor blockers (ARBs); Antihypertensive therapy; AT1 receptor antagonists; CYP1A2; CYP2C9; CYP3A4; Cytochrome P450 (CYP) metabolism; Drug interactions

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; IRBESARTAN; ITRACONAZOLE; LITHIUM; LOSARTAN; NIFEDIPINE; OLMESARTAN; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; WARFARIN;

EID: 12544256886     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.1.7     Document Type: Review
Times cited : (11)

References (94)
  • 2
    • 0037181148 scopus 로고    scopus 로고
    • Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study
    • VASAN RS, BEISER A, SESHADRI S et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 287:1003-1010.
    • (2002) JAMA , vol.287 , pp. 1003-1010
    • Vasan, R.S.1    Beiser, A.2    Seshadri, S.3
  • 3
    • 0038460302 scopus 로고    scopus 로고
    • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report
    • CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report. JAMA (2003) 289:2560-2572.
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 4
    • 0027461577 scopus 로고
    • Single-drug therapy for hypertension in men - A comparison of six antihypertensive agents with placebo
    • MATERSON BJ, REDA DJ, CUSHMAN WC et al.: Single-drug therapy for hypertension in men - a comparison of six antihypertensive agents with placebo. N. Engl. J. Med. (1993) 328:914-921.
    • (1993) N. Engl. J. Med. , vol.328 , pp. 914-921
    • Materson, B.J.1    Reda, D.J.2    Cushman, W.C.3
  • 5
    • 0028930346 scopus 로고
    • Department of Veterans Affairs singic-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group - Antihypertensive Agents
    • MATERSON BJ, REDA DJ, CUSHMAN WC: Department of Veterans Affairs singic-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group - Antihypertensive Agents. Am. J. Hypertens. (1995) 8:189-192.
    • (1995) Am. J. Hypertens. , vol.8 , pp. 189-192
    • Mateson, B.J.1    Reda, D.J.2    Cushman, W.C.3
  • 6
    • 0035148501 scopus 로고    scopus 로고
    • Baseline characteristics and elderly blood pressure control in the CONVINCE trial
    • BLACK HR, ELLIOTT WJ, NEATON JD et al.: Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension (2001) 37:12-18.
    • (2001) Hypertension , vol.37 , pp. 12-18
    • Black, H.R.1    Elliott, W.J.2    Neaton, J.D.3
  • 7
    • 0036863587 scopus 로고    scopus 로고
    • Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • CUSHMAN WC, FORD CE, CUTLER JA et al.: Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (2002) 4:393-404.
    • (2002) J. Clin. Hypertens. , vol.4 , pp. 393-404
    • Cushman, W.C.1    Ford, C.E.2    Cutler, J.A.3
  • 8
  • 9
    • 0031746034 scopus 로고    scopus 로고
    • Important drug-drug interactions in the elderly
    • SEYMOUR RM, ROUTLEDGE PA: Important drug-drug interactions in the elderly. Drugs Aging (1998) 12:485-494.
    • (1998) Drugs Aging , vol.12 , pp. 485-494
    • Seymour, R.M.1    Routledge, P.A.2
  • 11
    • 0028453113 scopus 로고
    • Polypharmacy in the aged. Practical solutions
    • STEWART RB, COOPER JW: Polypharmacy in the aged. Practical solutions. Drugs Aging (1994) 4:449-461.
    • (1994) Drugs Aging , vol.4 , pp. 449-461
    • Stewart, R.B.1    Cooper, J.W.2
  • 12
    • 0043124614 scopus 로고    scopus 로고
    • Drug interactions with ARBs: A comparison with other antihypertensives
    • UNGER T, KASCHINA E: Drug interactions with ARBs: a comparison with other antihypertensives. Drug Saf. (2003) 26 707-720.
    • (2003) Drug Saf. , vol.26 , pp. 707-720
    • Unger, T.1    Kaschina, E.2
  • 13
    • 0026890830 scopus 로고
    • Adverse reactions as a cause of hospital admission in the aged
    • BEARD K: Adverse reactions as a cause of hospital admission in the aged. Drugs Aging (1992) 2:356-367.
    • (1992) Drugs Aging , vol.2 , pp. 356-367
    • Beard, K.1
  • 14
    • 0031012726 scopus 로고    scopus 로고
    • The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group
    • BATES DW, SPELL N, CULLEN DJ et al.: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA (1997) 277:307-311.
    • (1997) JAMA , vol.277 , pp. 307-311
    • Bates, D.W.1    Spell, N.2    Cullen, D.J.3
  • 15
    • 0032522873 scopus 로고    scopus 로고
    • Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
    • LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279:1200-1205.
    • (1998) JAMA , vol.279 , pp. 1200-1205
    • Lazarou, J.1    Pomeanz, B.H.2    Corey, P.N.3
  • 16
    • 0037169960 scopus 로고    scopus 로고
    • Implications of cytochrome P450 interactions when prescribing medication for hypertension
    • FLOCKHART DA, TANUS-SANTOS JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. (2002) 162: 405-412.
    • (2002) Arch. Intern. Med. , vol.162 , pp. 405-412
    • Flockhart, D.A.1    Tanus-Santos, J.E.2
  • 17
    • 0034631883 scopus 로고    scopus 로고
    • Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors?
    • GROSSMAN E, MESSERLI FH, NEUTEL JM: Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch. Intern. Med. (2000) 160:1905-1911.
    • (2000) Arch. Intern. Med. , vol.160 , pp. 1905-1911
    • Grossman, E.1    Messerli, F.H.2    Neutel, J.M.3
  • 18
    • 0035852724 scopus 로고    scopus 로고
    • Angiotensin II type 1 receptor blockers
    • BURNIER M: Angiotensin II type 1 receptor blockers. Circulation (2001) 103:904-912.
    • (2001) Circulation , vol.103 , pp. 904-912
    • Burnier, M.1
  • 19
    • 0034869208 scopus 로고    scopus 로고
    • Comparison of angiotensin II receptor antagonists
    • KIRCH W, HORN B, SCHWEIZER J: Comparison of angiotensin II receptor antagonists. Eur. J. Clin. Invest. (2001) 31 698-706.
    • (2001) Eur. J. Clin. Invest. , vol.31 , pp. 698-706
    • Kirch, W.1    Horn, B.2    Schweizer, J.3
  • 20
    • 0037527647 scopus 로고    scopus 로고
    • 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension
    • GUIDELINES COMMITTEE
    • GUIDELINES COMMITTEE: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011-1053.
    • (2003) J. Hypertens. , vol.21 , pp. 1011-1053
  • 21
    • 0031948041 scopus 로고    scopus 로고
    • Comparative pharmacology of the angiotensin II receptor antagonists
    • DZIELAK DJ: Comparative pharmacology of the angiotensin II receptor antagonists. Expert Opin. Investig. Drugs (1998) 7 741-751.
    • (1998) Expert Opin. Investig. Drugs , vol.7 , pp. 741-751
    • Dzielak, D.J.1
  • 22
    • 0030053138 scopus 로고    scopus 로고
    • Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy
    • WEXLER RR, GREENLEE WJ, IRVIN JD et al.: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J. Med. Chem. (1996) 39:625-656.
    • (1996) J. Med. Chem. , vol.39 , pp. 625-656
    • Wexler, R.R.1    Greenlee, W.J.2    Irvin, J.D.3
  • 23
    • 0029025655 scopus 로고
    • Recent advances: The cytochrome P450 enzymes
    • SLAUGHTER RL, EDWARDS DJ: Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. (1995) 29:619-624.
    • (1995) Ann. Pharmacother. , vol.29 , pp. 619-624
    • Slaughter, R.L.1    Edwards, D.J.2
  • 24
    • 0034119823 scopus 로고    scopus 로고
    • In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists
    • TAAVITSAINEN P, KIUKAANNIEMI K, PELKONEN O: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol. (2000) 56 135-140.
    • (2000) Eur. J. Clin. Pharmacol. , vol.56 , pp. 135-140
    • Taavitsainen, P.1    Kiukaanniemi, K.2    Pelkonen, O.3
  • 25
    • 0031957174 scopus 로고    scopus 로고
    • Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
    • KAUKONEN KM, OLKKOLA KT, NEUVONEN PJ: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. (1998) 53:445-449.
    • (1998) Eur. J. Clin. Pharmacol. , vol.53 , pp. 445-449
    • Kaukonen, K.M.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 26
    • 0030724427 scopus 로고    scopus 로고
    • Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
    • KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. (1997) 62:417-425.
    • (1997) Clin. Pharmacol. Ther. , vol.62 , pp. 417-425
    • Kazierad, D.J.1    Martin, D.E.2    Blum, R.A.3
  • 27
    • 0036739717 scopus 로고    scopus 로고
    • Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers
    • FISCHER TL, PIEPER JA, GRAFF DW et al.: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. (2002) 72:238-246.
    • (2002) Clin. Pharmacol. Ther. , vol.72 , pp. 238-246
    • Fisher, T.L.1    Pieper, J.A.2    Graff, D.W.3
  • 28
  • 31
    • 0029954329 scopus 로고    scopus 로고
    • Angiotensin II receptor antagonists: The prototype losartan
    • SCHAEFER KL, PORTER JA: Angiotensin II receptor antagonists: the prototype losartan. Ann. Pharmacother. (1996) 30:625-636.
    • (1996) Ann. Pharmacother. , vol.30 , pp. 625-636
    • Schaefer, K.L.1    Porter, J.A.2
  • 32
    • 0028849020 scopus 로고
    • Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist
    • GOLDBERG MR, LO MW, BRADSTREET TE, RITTER MA, HOGLUND P: Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur. J. Clin. Pharmacol. (1995) 49:115-119.
    • (1995) Eur. J. Clin. Pharmacol. , vol.49 , pp. 115-119
    • Goldberg, M.R.1    Lo, M.W.2    Bradstreet, T.E.3    Ritter, M.A.4    Hoglund, P.5
  • 34
    • 0035022460 scopus 로고    scopus 로고
    • The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA
    • SCHMIDT A, GRUBER U, BOHMIG G, KOLLER E, MAYER G: The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol. Dial. Transplant. (2001) 16:1034-1037.
    • (2001) Nephrol. Dial. Transplant. , vol.16 , pp. 1034-1037
    • Schmidt, A.1    Gruber, U.2    Bohmig, G.3    Koller, E.4    Mayer, G.5
  • 35
    • 0031741629 scopus 로고    scopus 로고
    • Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients
    • DEL CASTILLO D, CAMPISTOL JM, GUIRADO L et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int. (1998) 68:S135-S139.
    • (1998) Kidney Int. , vol.68
    • Del Castillo, D.1    Campistol, J.M.2    Guirado, L.3
  • 36
    • 0034896135 scopus 로고    scopus 로고
    • Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers
    • ZAIDENSTEIN R, SOBACK S, GIPS M et al.: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther. Drug Monit. (2001) 23:369-373.
    • (2001) Ther. Drug Monit. , vol.23 , pp. 369-373
    • Zaidenstein, R.1    Soback, S.2    Gips, M.3
  • 37
    • 6544294068 scopus 로고    scopus 로고
    • Effect of pain and nonsteroidal analgesics on blood pressure
    • CHAWLA PS, KOCHAR MS: Effect of pain and nonsteroidal analgesics on blood pressure. WMJ (1999) 98:22-29.
    • (1999) WMJ , vol.98 , pp. 22-29
    • Chawla, P.S.1    Kochar, M.S.2
  • 38
    • 0033817582 scopus 로고    scopus 로고
    • Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients
    • CONLIN PR, MOORE TJ, SWARTZ SL et al.: Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension (2000) 36:461-465.
    • (2000) Hypertension , vol.36 , pp. 461-465
    • Conlin, P.R.1    Moore, T.J.2    Swartz, S.L.3
  • 39
    • 0032835496 scopus 로고    scopus 로고
    • Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan
    • NAWARSKAS JJ, TOWNSEND RR, CIRIGLIANO MD, SPINLER SA: Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am. J. Hypertens. (1999) 12:784-789.
    • (1999) Am. J. Hypertens. , vol.12 , pp. 784-789
    • Nawarskas, J.J.1    Townsend, R.R.2    Cirigliano, M.D.3    Spinler, S.A.4
  • 40
    • 0029593383 scopus 로고
    • Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers
    • DE SMET M, SCHOORS DF, DE MEYER G et al.: Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br. J. Clin. Pharmacol. (1995) 40 571-575.
    • (1995) Br. J. Clin. Pharmacol. , vol.40 , pp. 571-575
    • De Smet, M.1    Schoors, D.F.2    De Meyer, G.3
  • 41
    • 0028847447 scopus 로고
    • Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin
    • KONG AN, TOMASKO L, WALDMAN SA et al.: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. (1995) 35:1008-1015.
    • (1995) J. Clin. Pharmacol. , vol.35 , pp. 1008-1015
    • Kong, A.N.1    Tomasko, L.2    Waldman, S.A.3
  • 42
    • 0029597865 scopus 로고
    • Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide
    • MCCREA JB, LO MW, TOMASKO L et al.: Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J. Clin. Pharmacol. (1995) 35:1200-1206.
    • (1995) J. Clin. Pharmacol. , vol.35 , pp. 1200-1206
    • McCrea, J.B.1    Lo, M.W.2    Tomasko, L.3
  • 43
    • 0029915382 scopus 로고    scopus 로고
    • Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients
    • RUILOPE LM, SIMPSON RL, TOH J, ARCURI KE, GOLDBERG AI, SWEET CS: Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press. (1996) 5:32-40.
    • (1996) Blood Press. , vol.5 , pp. 32-40
    • Ruilope, L.M.1    Simpson, R.L.2    Toh, J.3    Arcuri, K.E.4    Goldberg, A.I.5    Sweet, C.S.6
  • 44
    • 0033822125 scopus 로고    scopus 로고
    • Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases
    • YAMAMOTO T, MORIWAKI Y, TAKAHASHI S, TSUTSUMI Z, HADA T: Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J. Rheumatol. (2000) 27:2232-2236.
    • (2000) J. Rheumatol. , vol.27 , pp. 2232-2236
    • Yamamoto, T.1    Moriwaki, Y.2    Takahashi, S.3    Tsutsumi, Z.4    Hada, T.5
  • 46
    • 1542510891 scopus 로고    scopus 로고
    • Uric acid: Role in cardiovascular disease and effects of losartan
    • ALDERMAN M, AIYER KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. (2004) 20 369-379.
    • (2004) Curr. Med. Res. Opin. , vol.20 , pp. 369-379
    • Alderman, M.1    Aiyer, K.J.2
  • 47
    • 0032722880 scopus 로고    scopus 로고
    • Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
    • SHAHINFAR S, SIMPSON RL, CARIDES AD et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. (1999) 56:1879-1885.
    • (1999) Kidney Int. , vol.56 , pp. 1879-1885
    • Shahinfar, S.1    Simpson, R.L.2    Carides, A.D.3
  • 48
    • 0030763446 scopus 로고    scopus 로고
    • Lithium intoxication in an elderly patient after combined treatment with losartan
    • BLANCHE P, RAYNAUD E, KEROB D, GALEZOWSKI N: Lithium intoxication in an elderly patient after combined treatment with losartan. Eur. J. Clin. Pharmacol. (1997) 52:501.
    • (1997) Eur. J. Clin. Pharmacol. , vol.52 , pp. 501
    • Blanche, P.1    Raynaud, E.2    Kerob, D.3    Galezoski, N.4
  • 50
    • 0031022244 scopus 로고    scopus 로고
    • Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
    • WALDMEIER F, FLESCH G, MULLER P et al.: Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica (1997) 27:59-71.
    • (1997) Xenobiotica , vol.27 , pp. 59-71
    • Waldmeier, F.1    Flesch, G.2    Muller, P.3
  • 51
    • 0008761345 scopus 로고    scopus 로고
    • Comparison of enalapril and valsartan in cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet
    • LASSILA M, FINCKENBERG P, PERE AK et al.: Comparison of enalapril. and valsartan in cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br. J. Pharmacol. (2000) 130:1339-1347.
    • (2000) Br. J. Pharmacol. , vol.130 , pp. 1339-1347
    • Lassila, M.1    Finckenberg, P.2    Pere, A.K.3
  • 52
    • 0034039783 scopus 로고    scopus 로고
    • Potential drug interaction between lithium and valsartan
    • LEUNG M, REMICK RA: Potential drug interaction between lithium and valsartan. J. Clin. Psychopharmacol. (2000) 20 392-393.
    • (2000) J. Clin. Psychopharmacol. , vol.20 , pp. 392-393
    • Leung, M.1    Remick, R.A.2
  • 54
    • 0030859254 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide
    • BINDSCHEDLER M, DEGEN P, FLESCH G, DE GASPARO M, PREISWERK G: Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur. J. Clin. Pharmacol. (1997) 52 371-378.
    • (1997) Eur. J. Clin. Pharmacol. , vol.52 , pp. 371-378
    • Bindschedler, M.1    Degen, P.2    Flesch, G.3    De Gasparo, M.4    Preiswerk, G.5
  • 55
    • 0031969656 scopus 로고    scopus 로고
    • An interaction study with cimetidine and the new angiotensin II antagonist valsartan
    • SCHMIDT EK, ANTONIN KH, FLESCH G, RACINE-POON A: An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur. J. Clin. Pharmacol. (1998) 53:451-458.
    • (1998) Eur. J. Clin. Pharmacol. , vol.53 , pp. 451-458
    • Schmidt, E.K.1    Antonin, K.H.2    Flesch, G.3    Racine-Poon, A.4
  • 56
    • 12544253051 scopus 로고    scopus 로고
    • NO AUTHORS LISTED: Diovan® (valsartan) - Sifton DW (Ed.), Montvale (NJ), Medical Economics Co., Inc
    • NO AUTHORS LISTED: Diovan® (valsartan) - In: Physicians desk reference (Volume 55). Sifton DW (Ed.), Montvale (NJ), Medical Economics Co., Inc. (2001):2166-2167.
    • (2001) Physicians Desk Reference , vol.55 , pp. 2166-2167
  • 57
    • 0027281668 scopus 로고
    • Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
    • NODA M, SHIBOUTAY, INADA Y et al.: Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol. (1993) 46:311-318.
    • (1993) Biochem. Pharmacol. , vol.46 , pp. 311-318
    • Noda, M.1    Shiboutay, A.2    Inada, Y.3
  • 60
    • 0036271824 scopus 로고    scopus 로고
    • Candesartan cilexetil: An update of its use in essential hypertension
    • EASTHOPE SE, JARVIS B: Candesartan cilexetil: an update of its use in essential hypertension. Drugs (2002) 62:1253-1287.
    • (2002) Drugs , vol.62 , pp. 1253-1287
    • Easthope, S.E.1    Jarvis, B.2
  • 61
    • 0027490969 scopus 로고
    • Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist
    • CAZAUBON C, GOUGAT J, BOUSQUET F et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. (1993) 265:826-834.
    • (1993) J. Pharmacol. Exp. Ther. , vol.265 , pp. 826-834
    • Cazaubon, C.1    Gougat, J.2    Bousquet, F.3
  • 62
    • 0028990719 scopus 로고
    • Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action
    • CHRISTOPHE B, LIBON R, CAZAUBON C, NISATO D, MANNING A, CHATELAIN P: Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Eur. J. Pharmacol. (1995) 281:161-171.
    • (1995) Eur. J. Pharmacol. , vol.281 , pp. 161-171
    • Christophe, B.1    Libon, R.2    Cazaubon, C.3    Nisato, D.4    Manning, A.5    Chatelain, P.6
  • 63
    • 0031418316 scopus 로고    scopus 로고
    • The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations
    • BRUNNER HR: The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am. J. Hyperterns. (1997) 10:311-317.
    • (1997) Am. J. Hyperterns. , vol.10 , pp. 311-317
    • Brunner, H.R.1
  • 64
    • 0032935655 scopus 로고    scopus 로고
    • Role of cytochrome P4502C9 in irbesartan oxidation by human liver microsomes
    • BOURRIE M, MEUNIER V, BERGER Y, FABRE G: Role of cytochrome P4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. (1999) 27:288-296.
    • (1999) Drug Metab. Dispos. , vol.27 , pp. 288-296
    • Bourrie, M.1    Meunier, V.2    Berger, Y.3    Fabre, G.4
  • 65
    • 0032834554 scopus 로고    scopus 로고
    • Irbesartan does not affect the steady-state pharmacodynamic and pharmacokinetics of warfarin
    • MANGOLD B, GIELSDORF W. MARINO MR: Irbesartan does not affect the steady-state pharmacodynamic and pharmacokinetics of warfarin. Eur. J. Clin. Pharmacol. (1999) 55:593-598.
    • (1999) Eur. J. Clin. Pharmacol. , vol.55 , pp. 593-598
    • Mangold, B.1    Gielsdorf, W.2    Marino, M.R.3
  • 67
    • 0033672869 scopus 로고    scopus 로고
    • Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects
    • MARINO MR, VACHHARAJANI NN, HADJILAMBRIS OW: Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J. Clin. Pharmacol. (2000) 40:875-879.
    • (2000) J. Clin. Pharmacol. , vol.40 , pp. 875-879
    • Marino, M.R.1    Vachharajani, N.N.2    Hadjilambris, O.W.3
  • 68
    • 0035820295 scopus 로고    scopus 로고
    • Renal safety of combined cyclooxygenase-2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion
    • KISTLER T, AMBUHL PM: Renal safety of combined cyclooxygenase-2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med. Wkly (2001) 131:193-198.
    • (2001) Swiss Med. Wkly. , vol.131 , pp. 193-198
    • Kistler, T.1    Ambuhl, P.M.2
  • 69
    • 0032900062 scopus 로고    scopus 로고
    • A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies
    • BLUM RA, KAZIERAD DJ, TENERO DM: A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy (1999) 19:79-85.
    • (1999) Pharmacotherapy , vol.19 , pp. 79-85
    • Blum, R.A.1    Kazierad, D.J.2    Tenero, D.M.3
  • 70
    • 0035215475 scopus 로고    scopus 로고
    • Eprosartan versus enalapril in elderly patients with hypertension: A double-blind, randomized trial
    • RUILOPE L, JAGER B, PRICHARD B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. (2001) 10:223-229.
    • (2001) Blood Press. , vol.10 , pp. 223-229
    • Ruilope, L.1    Jager, B.2    Prichard, B.3
  • 71
    • 0031947633 scopus 로고    scopus 로고
    • Drug interactions at the renal level. Implications for drug development
    • BONATE PL, REITH K, WEIR S: Drug interactions at the renal level. Implications for drug development. Clin. Pharmacokinet. (1998) 34:375-404.
    • (1998) Clin. Pharmacokinet. , vol.34 , pp. 375-404
    • Bonate, P.L.1    Reith, K.2    Weir, S.3
  • 72
    • 0030874256 scopus 로고    scopus 로고
    • Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin healthy male volunteers
    • MARTIN DE, TOMPSON D, BOIKE SC et al.: Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin healthy male volunteers. Br. J. Clin. Pharmacol. (1997) 43:661-664.
    • (1997) Br. J. Clin. Pharmacol. , vol.43 , pp. 661-664
    • Martin, D.E.1    Tompson, D.2    Boike, S.C.3
  • 73
    • 0031903838 scopus 로고    scopus 로고
    • Eprosartan does not affect the pharmacodynamic of warfarin
    • KAZIERAD DJ, MARTIN DE, ILSON B et al.: Eprosartan does not affect the pharmacodynamic of warfarin. J. Clin. Pharmacol. (1998) 38:649-653.
    • (1998) J. Clin. Pharmacol. , vol.38 , pp. 649-653
    • Kazierad, D.J.1    Martin, D.E.2    Ilson, B.3
  • 74
    • 0030939617 scopus 로고    scopus 로고
    • Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patient, with Type II diabetes mellitus
    • MARTIN DE, DECHERNEY GS, ILSON BE et al.: Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patient, with Type II diabetes mellitus. J. Clin. Pharmacol. (1997) 37:155-159.
    • (1997) J. Clin. Pharmacol. , vol.37 , pp. 155-159
    • Martin, D.E.1    Decherney, G.S.2    Ilson, B.E.3
  • 75
    • 0031934526 scopus 로고    scopus 로고
    • Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
    • TENERO DM, MARTIN DE, ILSON BE et al.: Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. Ann. Pharmacother. (1998) 32:304-308.
    • (1998) Ann. Pharmacother. , vol.32 , pp. 304-308
    • Tenero, D.M.1    Martin, D.E.2    Ilson, B.E.3
  • 76
    • 0030724427 scopus 로고    scopus 로고
    • Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
    • KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. (1997) 62:417-425.
    • (1997) Clin. Pharmacol. Ther. , vol.62 , pp. 417-425
    • Kazierad, D.J.1    Martin, D.E.2    Blum, R.A.3
  • 77
    • 0036720461 scopus 로고    scopus 로고
    • In vitro and in vivo characterization of the activity of telmisartan: An insurmountable angiotensin II receptor antagonist
    • MAILLARD MP, PERREGAUX C, CENTENO C et al.: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. (2002) 302:1089-1095.
    • (2002) J. Pharmacol. Exp. Ther. , vol.302 , pp. 1089-1095
    • Maillard, M.P.1    Perregaux, C.2    Centeno, C.3
  • 78
    • 0033731288 scopus 로고    scopus 로고
    • Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
    • STANGIER J, SU CA: Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1347-1354.
    • (2000) J. Clin. Pharmacol. , vol.40 , pp. 1347-1354
    • Stangier, J.1    Su, C.A.2
  • 79
    • 0034874986 scopus 로고    scopus 로고
    • Telmisartan: A review of its use in hypertension
    • SHARPE M, JARVIS B, GOA KL: Telmisartan: a review of its use in hypertension. Drugs (2001) 61:1501-1529.
    • (2001) Drugs , vol.61 , pp. 1501-1529
    • Sharpe, M.1    Jarvis, B.2    Goa, K.L.3
  • 80
    • 0033749283 scopus 로고    scopus 로고
    • Pharmacokinetics of acetaminophen and ibuprofen when co-administered with telmisartan in healthy volunteers
    • STANGIER J, SU CA, FRAUNHOFER A, TETZLOFF W: Pharmacokinetics of acetaminophen and ibuprofen when co-administered with telmisartan in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1338-1346.
    • (2000) J. Clin. Pharmacol. , vol.40 , pp. 1338-1346
    • Stangier, J.1    Su, C.A.2    Fraunhofer, A.3    Tetzloff, W.4
  • 81
    • 0033732238 scopus 로고    scopus 로고
    • Steady-state pharmacodynamics, and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
    • STANGIER J, SU CA, HENDRIKS MG et al.: Steady-state pharmacodynamics, and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J. Clin. Pharmacol. (2000) 40:1331-1337.
    • (2000) J. Clin. Pharmacol. , vol.40 , pp. 1331-1337
    • Stangier, J.1    Su, C.A.2    Hendriks, M.G.3
  • 82
    • 0033748479 scopus 로고    scopus 로고
    • The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
    • STANGIER J, SU CA, HENDRIKS MG et al.: The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J. Clin. Pharmacol. (2000) 40:1373-1379.
    • (2000) J. Clin. Pharmacol. , vol.40 , pp. 1373-1379
    • Stangier, J.1    Su, C.A.2    Hendriks, M.G.3
  • 83
    • 0035131633 scopus 로고    scopus 로고
    • Effects of the replacement of the angiotensin-converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin-converting enzyme inhibition (REPLACE) investigators
    • DUNSELMAN PH: Effects of the replacement of the angiotensin-converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin-converting enzyme inhibition (REPLACE) investigators. Int. J. Cardiol. (2001) 77:131-138.
    • (2001) Int. J. Cardiol. , vol.77 , pp. 131-138
    • Dunselman, P.H.1
  • 84
    • 0028792103 scopus 로고
    • Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
    • MIZUNO M, SADA T, IKEDA M et al.: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol. (1995) 285:181-188.
    • (1995) Eur. J. Pharmacol. , vol.285 , pp. 181-188
    • Mizuno, M.1    Sada, T.2    Ikeda, M.3
  • 85
    • 0034951293 scopus 로고    scopus 로고
    • In vitro and in vivo pharmacology of olmesartan medoxomil, an angiorensin II type AT1 receptor antagonist
    • KOIKE H, SADA T, MIZUNO M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiorensin II type AT1 receptor antagonist. J. Hypertens. Suppl. (2001) 19:3-14.
    • (2001) J. Hypertens. Suppl. , vol.19 , pp. 3-14
    • Koike, H.1    Sada, T.2    Mizuno, M.3
  • 86
    • 0036071006 scopus 로고    scopus 로고
    • Olmesartan medoxomil
    • WARNER GT, JARVIS B: Olmesartan medoxomil. Drugs (2002) 62:1345-1353.
    • (2002) Drugs , vol.62 , pp. 1345-1353
    • Warner, G.T.1    Jarvis, B.2
  • 87
    • 0034956326 scopus 로고    scopus 로고
    • The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
    • LAEIS P, PUCHLER K, KIRCH W: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. (2001) 19:21-32.
    • (2001) J. Hypertens. , vol.19 , pp. 21-32
    • Laeis, P.1    Puchler, K.2    Kirch, W.3
  • 89
    • 0023261485 scopus 로고
    • Captopril and hydrochlorothiazide: Rationale for their combination
    • AMBROSIONI E, BORGHI C, COSTA FV: Captopril and hydrochlorothiazide: rationale for their combination. Br. J. Clin. Pharmacol. (1987) 23:43-50.
    • (1987) Br. J. Clin. Pharmacol. , vol.23 , pp. 43-50
    • Ambrosioni, E.1    Borghi, C.2    Costa, F.V.3
  • 90
    • 0020404274 scopus 로고
    • Different interactions of indomethacin and sulindac with thiazides in hypertension
    • STEINESS E, WALDORFF S: Different interactions of indomethacin and sulindac with thiazides in hypertension. Br. Med. J. (1982) 285:1702-1703.
    • (1982) Br. Med. J. , vol.285 , pp. 1702-1703
    • Steiness, E.1    Waldorff, S.2
  • 91
    • 0027285939 scopus 로고
    • Pharmacokinetic drug interactions with ACE inhibitors
    • SHIONOIRI H: Pharmacokinetic drug interactions with ACE inhibitors. Clin. Pharmacokinet. (1993) 25:20-58.
    • (1993) Clin. Pharmacokinet. , vol.25 , pp. 20-58
    • Shionoiri, H.1
  • 92
    • 0030062506 scopus 로고    scopus 로고
    • Lithium and angiotensin-converting enzyme inhibitors: Evaluation of a potential interaction
    • FINLEY PR, O'BRIEN JG, COLEMAN RW: Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J. Clin. Pyschopharmacol. (1996) 16:68-71.
    • (1996) J. Clin. Pyschopharmacol. , vol.16 , pp. 68-71
    • Finley, P.R.1    O'brien, J.G.2    Coleman, R.W.3
  • 93
    • 2342557311 scopus 로고    scopus 로고
    • Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure
    • CAPPELLI A, PERICOT MOHR GL G, GALLELLI A et al.: Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure. J. Med. Chem. (2004) 47:2574-2586.
    • (2004) J. Med. Chem. , vol.47 , pp. 2574-2586
    • Cappelli, A.1    Pericot Mohr, G.L.G.2    Gallelli, A.3
  • 94
    • 1942452358 scopus 로고    scopus 로고
    • Role of angiotensin II Type 2 receptors and kinins in the cardioprotective effect of angiotensin II Type 1 receptor antagonists in rats with heart failure
    • LIU YH, YANG XP, SHESELY EG, SANKEY SS, CARRETERO OA: Role of angiotensin II Type 2 receptors and kinins in the cardioprotective effect of angiotensin II Type 1 receptor antagonists in rats with heart failure. J. Am. Coll. Cardiol. (2004) 43:1473-1480.
    • (2004) J. Am. Coll. Cardiol. , vol.43 , pp. 1473-1480
    • Liu, Y.H.1    Yang, X.P.2    Shesely, E.G.3    Sankey, S.S.4    Carretero, O.A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.